parsisotope
Order registration
| Contact Us |

Follow Us:

LinkedIn
Instagram
Telegram
YouTube
mail

info@Parsisotope.com

phone

+98-2142180000

location_on

No.88, West 23rd St.Azadegan Blvd. South Sheykh Bahaie Ave. Tehran, Iran

language
PersianSpanishArabic

PARS‑DTPA® Kit

 Sterile, NonPyrogen Lyophilized Powder

done
KIT FOR THE PREPARATION OF PENTEATE (Sn) Tc-99m INJECTION
done
SPECT Imaging
done
Diagnostic
circle
About the Product

PARS‑DTPA® is a sterile, non‑pyrogen lyophilized powder kit formulated for the preparation of 99mTc‑DTPA, intended solely for diagnostic use. After radiolabeling with Tc‑99m, the resulting radiopharmaceutical is primarily used for dynamic renal imaging. Each DTPA kit vial contains 20 mg of diethylenetriaminepentaacetic acid as a sterile, non‑pyrogen lyophilized powder, ready for intravenous administration.

circle
Applications
  • Primary application in measuring glomerular filtration rate (GFR) in renal scintigraphy
  • Utilization in blood flow studies including the brain, heart, and other organs
  • Application in cerebrospinal fluid circulation assessment
  • Utilization in gastrointestinal transit studies
  • Application in pulmonary ventilation imaging
  • Suitable for evaluation and measurement of renal function in pediatric patients
circle
Mechanism of Action

Following intravenous administration, 99mTc‑DTPA distributes within the bloodstream and is primarily excreted via glomerular filtration, without being reabsorbed or metabolized by renal tissues. This property makes the measurement of its accumulation and excretion in the kidneys a reliable indicator of the glomerular filtration rate (GFR), thus reflecting actual kidney function. Through scintigraphic imaging, physicians can quantitatively and dynamically assess renal blood flow patterns, the rate of renal uptake, and the excretion kinetics of the agent. These findings are of considerable clinical importance in the early diagnosis of renal functional impairment, monitoring the progression of renal disease, evaluating treatment outcomes, and assessing patients with suspected renal failure.

circle
Preparation and Administration

Note: This pharmaceutical product is intended solely for use in nuclear medicine facilities by personnel experienced in handling radiopharmaceuticals.

The PARS‑DTPA® kit is radiolabeled with a specified amount of sterile, non‑pyrogen sodium pertechnetate injection (Na⁹⁹ᵐTcO₄), eluted from a ⁹⁹Mo/⁹⁹ᵐTc generator (at the prescribed activity), and is then prepared for intravenous administration.

The determination of the administered activity in pediatric patients, as well as the use of this radiopharmaceutical for blood flow studies (brain, heart, and other organs), cerebrospinal fluid circulation assessment, gastrointestinal transit studies, and pulmonary ventilation evaluation, is at the discretion of the referring physician and is based on clinical diagnosis.

circle
Box Contents

Each box contains one instruction leaflet and five DTPA kit vials, along with five labels specifically for the radiolabeling procedure.

circle
Composition

Diethylenetriaminepentaacetic Acid (20 mg)

Stannous Chloride Dihydrate

Ascorbic Acid

Potassium Chloride

circle
Storage Conditions
  • The DTPA kit should not be used after the expiration date.
  • Store the PARS‑DTPA® kit in a refrigerator (2°C to 8°C) and protected from light. The cold chain must be maintained under all circumstances.
  • After radiolabeling, 99mTc‑DTPA must be used within 6 hours and stored at 15°C to 25°C.
You must be logged in to post a comment.
Menu